Combined Detection of Islet Autoantibodies for Clinical Diagnosis of Type 1 Diabetes in the Low-Prevalence Population
- 8 December 2022
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 108 (6) , e326-e333
Abstract
Context: Single positive islet autoantibodies (IAbs), sometimes detected in healthy individuals and patients with low-risk of developing type 1 diabetes (T1D), are considered to be irrelevant to the development of diabetes, making it difficult to diagnose and classify adult-onset diabetes. Objective: To determine the significance and clinical value of IAbs in T1D diagnosis in the low-prevalence population, and to explore whether an electrochemiluminescence IAb detection assay can improve the clinical utility of IAbs in the immunodiagnosis of T1D in the low-prevalence population. Methods: A total of 633 newly diagnosed patients with adult-onset diabetes (≥18 years old) were divided into 2 groups according to their clinical phenotypes: 575 patients with age at diagnosis ≥35 years and body mass index (BMI) ≥ 24 kg/m2 were considered a low-prevalence population (population with a low prevalence of T1D) and the other 58 patients were considered a high-prevalence population. All the samples from 633 participants were tested with IAbs using standard radiobinding assays (RBAs) and electrochemiluminescence (ECL) assays in parallel. Results: Compared with the high-prevalence population, fewer positive IAbs (94/575, 16.3% vs 28/58, 48.3%) were detected in the low-prevalence population, and more of whom (69/94, 73.4% vs 9/28, 32.2%) were positive for a single IAb, with glutamate decarboxylase antibodies being the most prevalent single IAb. Single-IAb detection in the low-prevalence population did not always suggest the T1D phenotype. Combined detection of IAbs by RBA and ECL assay had a significant clinical utility to distinguish autoimmune diabetes in the low-prevalence population with low BMI, poor β-cell function at the diagnosis, and an accelerated decline in β-cell function during the follow-up. Conclusion: Combined autoantibody detection by RBA and ECL assays improved differentiating autoimmune from nonautoimmune diabetes in the low-prevalence population.Keywords
Funding Information
- National Natural Science Foundation of China (82170837, 81770777, 81900708)
- Nanjing Medical University
This publication has 30 references indexed in Scilit:
- GAD65 Autoantibodies Detected by Electrochemiluminescence Assay Identify High Risk for Type 1 DiabetesDiabetes, 2013
- Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in ChildrenJAMA, 2013
- Distinguishing Persistent Insulin Autoantibodies With Differential RiskDiabetes, 2011
- Discordant association of islet autoantibodies with high‐risk HLA genes in Chinese type 1 diabetesDiabetes/Metabolism Research and Reviews, 2011
- Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1Diabetes Care, 2009
- SlC30A8 Is a Major Target of Humoral Autoimmunity in Type 1 Diabetes and a Predictive Marker in PrediabetesAnnals of the New York Academy of Sciences, 2008
- GAD Autoantibody Affinity and Epitope Specificity Identify Distinct Immunization Profiles in Children at Risk for Type 1 DiabetesDiabetes, 2007
- In insulin-autoantibody-positive children from the general population, antibody affinity identifies those at high and low riskDiabetologia, 2005
- Absence of avidity maturation of autoantibodies to the protein tyrosine phosphatase-like IA-2 molecule and glutamic acid decarboxylase (GAD65) during progression to type 1 diabetesJournal of Autoimmunity, 2005
- Glutamate decarboxylase-, insulin-, and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children.Journal of Clinical Investigation, 1995